Text Size

Memantine Augmentation in Obsessive-Compulsive Disorder

This study has been completed.
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00264238
First received: December 9, 2005
Last updated: April 8, 2009
Last verified: April 2009
History of Changes
  Purpose

The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).


Condition Intervention
Obsessive-Compulsive Disorder
 Drug: Memantine

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Y-BOCS score at final study visit

Estimated Enrollment: 15
Study Start Date: January 2006
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Detailed Description:

The purpose of this study is to determine whether memantine (Namenda), in doses up to 20 mg/day, will be effective in treating the OCD of adult patients who have not responded to their OCD medication. Memantine is not FDA approved for OCD, but is approved for the treatment of Alzheimer's Disease. Memantine appears to work by regulating the activity of glutamate, one of the brain's specialized messenger chemicals, which may play a role in OCD. All patients in the study will receive memantine; no one will receive placebo.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • at least 18 years of age
  • suffering from OCD
  • Y-BOCS score of 18 or greater
  • taking a therapeutic dose of an anti-OCD medication specified in the protocol

Exclusion Criteria:- diagnosed with a mental disorder other than OCD

  • taking tiagabine or pregabalin
  • having had a previous trial of memantine
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00264238

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: John J Barry Stanford University
  More Information

No publications provided

Responsible Party: ohn J Barry, Principal Investigator, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT00264238     History of Changes
Other Study ID Numbers: SUSPO34313
Study First Received: December 9, 2005
Last Updated: April 8, 2009
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Obsessive-Compulsive Disorder
Anxiety Disorders
Mental Disorders
Memantine
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
 Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 21, 2013